GlaxoSmithKline PLC (NYSE:GSK) Shares Bought by Paloma Partners Management Co

Paloma Partners Management Co raised its position in GlaxoSmithKline PLC (NYSE:GSK) by 31.3% during the first quarter, Holdings Channel reports. The firm owned 13,002 shares of the pharmaceutical company’s stock after buying an additional 3,102 shares during the period. Paloma Partners Management Co’s holdings in GlaxoSmithKline PLC were worth $549,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the company. Dynamic Advisors Solutions LLC boosted its position in GlaxoSmithKline PLC by 1,411.4% in the first quarter. Dynamic Advisors Solutions LLC now owns 95,292 shares of the pharmaceutical company’s stock worth $4,017,000 after buying an additional 88,987 shares during the period. Augustine Asset Management Inc. boosted its position in shares of GlaxoSmithKline PLC by 23.6% in the first quarter. Augustine Asset Management Inc. now owns 17,585 shares of the pharmaceutical company’s stock worth $741,000 after buying an additional 3,355 shares during the last quarter. GW&K Investment Management LLC boosted its position in shares of GlaxoSmithKline PLC by 17.8% in the first quarter. GW&K Investment Management LLC now owns 1,017,202 shares of the pharmaceutical company’s stock worth $42,885,000 after buying an additional 153,555 shares during the last quarter. Raymond James Trust N.A. boosted its position in shares of GlaxoSmithKline PLC by 3.4% in the first quarter. Raymond James Trust N.A. now owns 132,266 shares of the pharmaceutical company’s stock worth $5,576,000 after buying an additional 4,401 shares during the last quarter. Finally, New England Research & Management Inc. boosted its position in shares of GlaxoSmithKline PLC by 1.5% in the first quarter. New England Research & Management Inc. now owns 10,506 shares of the pharmaceutical company’s stock worth $443,000 after buying an additional 156 shares during the last quarter. 8.96% of the stock is owned by institutional investors.

Shares of GlaxoSmithKline PLC (NYSE:GSK) opened at 42.75 on Monday. The company has a market cap of $104.44 billion, a price-to-earnings ratio of 48.14 and a beta of 1.05. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $45.58. The firm has a 50 day moving average price of $43.56 and a 200-day moving average price of $41.27.

GlaxoSmithKline PLC (NYSE:GSK) last posted its earnings results on Wednesday, April 26th. The pharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.62. The company had revenue of $9.23 billion for the quarter, compared to analysts’ expectations of $9.09 billion. GlaxoSmithKline PLC had a return on equity of 113.31% and a net margin of 5.48%. Equities research analysts anticipate that GlaxoSmithKline PLC will post $2.82 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, July 13th. Investors of record on Friday, May 12th were paid a $0.483 dividend. The ex-dividend date was Wednesday, May 10th. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.93 annualized dividend and a dividend yield of 4.52%. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 233.74%.

COPYRIGHT VIOLATION WARNING: This report was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.com-unik.info/2017/07/17/glaxosmithkline-plc-nysegsk-shares-bought-by-paloma-partners-management-co.html.

A number of brokerages have issued reports on GSK. ValuEngine cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Friday, June 16th. TheStreet raised GlaxoSmithKline PLC from a “c” rating to a “b” rating in a report on Friday, May 19th. Citigroup Inc. cut GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a report on Wednesday, July 5th. Finally, Berenberg Bank raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a report on Friday, May 26th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $45.25.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

What are top analysts saying about GlaxoSmithKline PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit